



Clover Corporation Limited

ABN 85 003 622 866

ASX ANNOUNCEMENT

20 March 2013

CLOVER CORPORATION – RESULTS FOR 6 MONTHS ENDED 31 JANUARY 2013

ORGANIC GROWTH CONTINUES

- Sales revenue increased by 12.5% over prior corresponding period to \$20.2 million.
- Reported Profit up by 56.6% to \$2.66 million. However, allowing for the \$0.97 million non-recurring cost associated with the joint venture Future Food Ingredients Pty Limited (FFI), underlying profit is in line with the same period last year.
- Re-signed 5 year supply contract with major multi-national infant formula company.
- Customer trials are underway evaluating new products released in 2011.
- Increased expenditure by \$0.1 million (14%) over pcp on the innovation pipeline.
- Phase 3 clinical study with Clover's proprietary preterm infant formula continues on time.
- Strong demand for Clover's products expected to continue in the second half of FY2013.
- Interim dividend of 0.5 cents per share, fully franked.

Clover Corporation Limited (Clover, ASX CLV) reported significant sales revenue growth of 12.5% to \$20.2 million (1H FY2012: \$17.9 million) during the first half of FY2013.

Sales of encapsulated ingredients for infant formula and related applications continue to grow, particularly in Asia and Oceania. The increase in sales revenue was positively affected in the Oceania region by changes in bi-lateral tariff reductions associated with infant formula exports from New Zealand and Australia to China, along with market success by our customers in the region.

Clover Corporation maintains strong mutually beneficial relationships with our customers based on proprietary technology, excellent product quality, focused support and innovation. This approach has lead to re-signing a 5 year supply agreement with a major multi-national infant formula manufacturer.

Clover continues to invest in the future with additional funding provided for the development of new products including the provision of the preterm infant formula for the current Phase 3 clinical study. This trial is on time for the delivery of preliminary results by the end of 2014. In addition the evaluation by customers of several new products is likely to lead to small initial sales in the second half of FY2013.

The company expects the strong demand for its products to continue for the second half of FY2013.

After careful consideration of the Company's short term cash requirements, the Board has approved a fully franked interim dividend of 0.5 cents per share in respect of the current financial year. Relevant dates for the dividend are as follows:

Ex-dividend Date: Tuesday 16 April 2013

Record Date: Monday 22 April 2013

Payment Date: Tuesday 30 April 2013

Company Contacts:

Ian Brown – Managing Director +612 9232 7166

Jaime Pinto – Company Secretary +612 9232 7166